Phase 2 Clinical Trial to Evaluate Pre-Operative Ivonescimab Treatment for High-Risk, Localized Clear Cell Renal Cell Carcinoma
Background
A Phase 2 clinical trial sponsored by City of Hope Medical Center commenced on June 8, 2026, and is currently recruiting. The trial aims to assess the efficacy of pre-operative ivonescimab administration in patients with high-risk, non-metastatic clear cell renal cell carcinoma.
Mechanism
Ivonescimab is a monoclonal antibody that inhibits tumor angiogenesis and helps immune cells recognize cancer cells. This dual action has the potential to suppress tumor growth and metastasis.
Clinical Design
The primary objective is to confirm pre-operative pathological response and safety, with the primary endpoint being tumor size reduction and the incidence of adverse events. Secondary endpoints include long-term efficacy, such as disease-free survival.
Differentiation from Current Standard of Care
The current standard of care for high-risk, localized renal cell carcinoma involves post-operative adjuvant immunotherapy. Pre-operative ivonescimab administration may facilitate surgery by reducing tumor size and lowering the risk of metastasis.
Expected Outcomes
If the clinical trial is successful, ivonescimab could be the first agent to enter the neoadjuvant market, potentially opening the door to combinations with other immunotherapies. Improved patient recovery and long-term survival rates are anticipated.
The successful neoadjuvant clinical trial of ivonescimab has the potential to provide a new treatment option in the high-risk, localized renal cell carcinoma market, significantly increasing corporate value. For job seekers or current professionals looking to enter the fields of new drug development and clinical operations, this represents a valuable opportunity to stay informed about the latest trends in immunotherapy research.
Source: ClinicalTrials.gov (api_ct)